Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data
Objective: To investigate the long-term effects of the adrenergic blocker carvedilol on I-MIBG myocardial uptake in subjects with REM sleep behavior disorder (RBD) and other…Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.
Objective: To compare improvement in tremor at 12 weeks with Zonisamide given in a dose of 25 mg along with other ant- parkinsonian drugs as…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…Validation of a real- time monitoring system to detect motor symptoms in patients with Parkinson´s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Our aim was to analyze the ability of system to combine information on OFF periods, falls and dyskinesias of patients with PD. Background: Levodopa…Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.
Objective: The objetive of this study was to compare the benefit of APO and STN-DBS in aPD in terms of motor (off daily hours, UPDRS…Evaluating a Novel Home-Based Care Pathway for People with Parkinson’s Disease
Objective: To evaluate the acceptability, feasibility, safety and effectiveness of a novel remotely delivered Parkinson’s care pathway. Background: Current care pathways for people with Parkinson’s…DOPAMINERGIC AND NON-DOPAMINERGIC TREATMENT AFTER DEEP BRAIN STIMULATION (DBS) IN PARKINSON DISEASE (PD). IMPORTANCE OF NON MOTOR SYMPTOMS (NMS)
Objective: To analyse global pharmacological adjustment after Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) patients, and secondarily its relation with Non Motor Symptoms (NMS).…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 132
- Next Page »